| Keifer Dewayne Richardson, PA-C | |
|
526 Richland Ave W, Aiken, SC 29801-3828 | |
| (803) 648-3130 | |
| Not Available |
| Full Name | Keifer Dewayne Richardson |
|---|---|
| Gender | Male |
| Speciality | Physician Assistant - Medical |
| Location | 526 Richland Ave W, Aiken, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174031660 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | PA2880 (South Carolina) | Secondary |
| 363AM0700X | Physician Assistant - Medical | 9335 (Georgia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Keifer Dewayne Richardson, PA-C 1120 15th St Ste Bi1056, Augusta, GA 30912-0004 Ph: (706) 721-3813 | Keifer Dewayne Richardson, PA-C 526 Richland Ave W, Aiken, SC 29801-3828 Ph: (803) 648-3130 |
News Archive
According to a new study from the Slone Epidemiology Center (SEC) at Boston University, African-American women who reported sexual or physical abuse before age 11 had a greater risk of uterine fibroids in adulthood compared with women who had no such abuse history.
The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many applications, one promising use is for the identification of certain proteins, called monoclonal antibodies, that are capable of seeking out and destroying harmful cells. Several companies have recently developed monoclonal antibodies as treatments for cancer, rheumatoid arthritis, and other conditions. Under an exclusive, worldwide license from the University of Rochester, Vaccinex is using the patented technology to discover and develop new monoclonal antibody therapies.
BioNanomatrix, Inc. has announced receipt of a Phase II grant from the National Human Genome Research Institute (NHGRI) of the U.S. National Institutes of Health (NIH).
Results from a Swedish study show that only a small proportion of depressed adolescents with hypomania spectrum episodes will develop bipolar disorder in adulthood.
Triple Ring Technologies, Inc., a leading provider of early-stage advanced research and development services, today announced that it has been awarded a Challenge Grant from the National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), as part of the American Recovery and Reinvestment Act (ARRA).
› Verified 9 days ago